[HTML][HTML] Improved survival with vemurafenib in melanoma with BRAF V600E mutation

…, A Testori, M Maio, D Hogg, P Lorigan… - … England Journal of …, 2011 - Mass Medical Soc
Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032)
have shown response rates of more than 50% in patients with metastatic melanoma with …

[HTML][HTML] Improved overall survival in melanoma with combined dabrafenib and trametinib

…, I Krajsova, A Hauschild, P Lorigan… - … England Journal of …, 2015 - Mass Medical Soc
Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as
monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or …

[HTML][HTML] Improved survival with ipilimumab in patients with metastatic melanoma

…, J Lutzky, P Lorigan… - … England Journal of …, 2010 - Mass Medical Soc
Background An improvement in overall survival among patients with metastatic melanoma
has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-…

[HTML][HTML] Pembrolizumab versus ipilimumab in advanced melanoma

…, C McNeil, M Lotem, J Larkin, P Lorigan… - … England Journal of …, 2015 - Mass Medical Soc
Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (…

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open …

…, CD Lao, GP Linette, L Thomas, P Lorigan… - The lancet …, 2015 - thelancet.com
Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody,
can result in durable responses in patients with melanoma who have progressed after …

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label …

…, C Garbe, A Testori, M Maio, P Lorigan… - The lancet …, 2014 - thelancet.com
Background In the BRIM-3 trial, vemurafenib was associated with risk reduction versus
dacarbazine of both death and progression in patients with advanced BRAF V600 mutation-…

[HTML][HTML] Adjuvant pembrolizumab versus placebo in resected stage III melanoma

…, JJ Grob, R Gutzmer, R Jamal, P Lorigan… - … England Journal of …, 2018 - Mass Medical Soc
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

…, MS Carlino, C McNeil, M Lotem, J Larkin, P Lorigan… - The Lancet, 2017 - thelancet.com
Background Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall
and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced …

[HTML][HTML] Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

…, J Schachter, G Linette, P Lorigan… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose In phase I/II trials, the cytotoxic T lymphocyte–associated antigen-4–blocking
monoclonal antibody tremelimumab induced durable responses in a subset of patients with …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

…, CM McNeil, M Lotem, JMG Larkin, P Lorigan… - The Lancet …, 2019 - thelancet.com
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first-…